Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sandostatin LAR in Androgen Independent Prostate Cancer
NCT00510224Phase 2Terminated
- Sponsor
- University of California, San Francisco
- Start
- Jul 2007
- Primary completion
- Aug 2009
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of Octreotide long-acting injection in prostate cancer (PCa), sponsored by University of California, San Francisco. Started Jul 2007; status: terminated.
02
Drugs
Octreotide long-acting injection
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00510224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00510224.